Endometrial evaluation prior to tamoxifen: Preliminary results of a prospective study;L'evaluation endometriale prealable au tamoxifene: Resultats preliminaires d'une etude prospective

Bulletin du Cancer

Volumn 85, Issue 8, 1998, Pages 721-724

  Berlière, Martine ^a   Galant, Christine ^a   Gillerot, Stéphane ^a   Charles, Alain ^a   Donnez, Jacques ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Endometrial carcinoma; High risk patients; Tamoxifen; Uterine screening

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYSTEROSCOPY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POLYP; POSTMENOPAUSE; PROSPECTIVE STUDY; TRANSVAGINAL ECHOGRAPHY; UTERUS MYOMA; ADENOMA; BREAST TUMOR; CARCINOMA IN SITU; ENDOMETRIUM TUMOR; FIBROMA;

ADENOMA; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA IN SITU; ENDOMETRIAL NEOPLASMS; FEMALE; FIBROMA; HUMANS; POLYPS; POSTMENOPAUSE; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 0032135025     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Nephen KP, Polec TC, Khan SA. Tamoxifen-induced proto-oncogene expression persists in uterine endometrial epithelium. Endocrinology 1996 ; 137 : 219-24.
2. Wogan GN. Review of the toxicology of tamoxifen. Semin Oncol 1997 ; 51 : 87-97.
3. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989 ; 1 : 117-20.
4. Magriples U, Naftolin F, Schwartz PC, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993 ; 11 : 485-90.
5. Sasco AJ, Raffi F, Satge D, Goburdhun J, Fallou HB, Leduc B. Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int J Gynaecol Obstet 1995 ; 48 : 307-10.
6. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerman DL, Cronin WN, et al. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the NSABP B 14. J Natl Cancer Inst 1994 ; 86 : 527-37.
7. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995 ; 87 : 645-51.
8. Neven P, De Muylder X, Van Belle Y, Campo R, Vanderick G. Tamoxifen and the uterus: women given this drug need careful assessment. Br Med J 1994 ; 309 : 1313-4.
9. Gal D, Kopel S, Basheukin M, Lebowicz J, Lev R, Tancer L. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer. Preliminary report. Gynecol Oncol 1991 ; 42 : 120-3.
10. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996 ; 32 : 1464-76.
11. Sasco AJ, Song AH, Gendr I, Zlatoff P, Bobin JY, Hallonet P, Leduc B. Cancer de l'endomètre et tamoxifene : discussion à partir d'une série de cas. Bull Cancer 1997 ; 84 : 51-60.
12. Kurman RJ, Norris HJ. Endometrial hyperplasia and related cellular changes. In : Kurman RJ. Blaustein's pathology of the female genital tract. 4th ed. New York, Springer Verlag, 1994 : 411-37.
13. Kurman RJ, Norris HJ. Endometrial carcinoma. In : Kurman RJ. Blaustein's pathology of the female genital tract. 4th ed. New York, Springer Verlag, 1994 : 439-86.